Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304445 | 0.79 | NUDT1 (0.43) | PDE10A | |
| SCHEMBL3304617 | 0.69 | S1PR1 (0.40) | — | |
| SCHEMBL3300152 | 0.67 | AHR (0.36) | AHR | |
| SCHEMBL25074680 | 0.67 | AHR (0.39) | PDE10AAHR | |
| SCHEMBL12079088 | 0.67 | PDE10A (0.39) | PDE10AAHR | |
| SCHEMBL13390440 | 0.67 | CYP11B2 (0.53) | PDE10AAHR | |
| SCHEMBL12078961 | 0.65 | AHR (0.34) | PDE10AAHR | |
| SCHEMBL12079172 | 0.63 | PDE10A (0.41) | PDE10AAHR | |
| SCHEMBL3302899 | 0.63 | AHR (0.36) | AHR | |
| SCHEMBL3299884 | 0.62 | HDAC4 (0.37) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | PDE10A 3911/4885MALT1 2167/4885AHR 91/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | PDE10A 3911/4885MALT1 2167/4885AHR 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.